ReviewCurrent rheumatology reports2015
The significance and management of thrombocytopenia in antiphospholipid syndrome.
Review in Current rheumatology reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 81 citations in OpenAlex.
- A novel aGAPSS-based nomogram for the prediction of ischemic stroke in patients with antiphospholipid syndrome.Frontiers in immunology · 2022Trial
- Thrombocytopenia in carriers and patients with antiphospholipid syndrome: insights from the nationwide START-APS registry.Internal and emergency medicine · 2026Article
- Fostamatinib treatment for patients with antiphospholipid syndrome and low platelet count: A case series.British journal of haematology · 2026Article
- Concomitant pulmonary embolism and severe thrombocytopenia associated with an APS-like autoimmune thrombophilic condition: a case report.BMC pulmonary medicine · 2026Article
- Enhanced type I interferon signature in primary APS patients is associated with thrombocytopenia.Frontiers in immunology · 2026Article
- Thrombolytic Therapy for Massive Pulmonary Embolism in an Antiphospholipid Syndrome Patient With Severe Thrombocytopenia: A Case Report.Clinical case reports · 2025Article
- Identifying Parameters Associated with Delayed Diagnosis in Thrombotic Antiphospholipid Syndrome: Data from China Prospective APS Cohort.Advances in therapy · 2025Article
- Severe thrombocytopenia is associated with adverse pregnancy outcomes in patients with obstetric antiphospholipid syndrome.European journal of medical research · 2025Observational
- Risk Factors for Recurrent Thrombosis in Patients with Antiphospholipid Syndrome-A Single-Centre Cohort Study.TH open : companion journal to thrombosis and haemostasis · 2025Article
- Case Report: Remission of a patient with complex combination of autoimmune diseases by anti-CD19 CAR-T cell therapy.Frontiers in immunology · 2025Article
- Antiphospholipid Antibodies Modify the Prognostic Value of Baseline Platelet Count for Clinical Outcomes After Ischemic Stroke.Journal of the American Heart Association · 2024Article
- Clinical characteristics and anticoagulation patterns of patients with acute pulmonary thromboembolism and hemoptysis.Pulmonary circulation · 2024Article
- Antiphospholipid antibodies as potential predictors of disease severity and poor prognosis in systemic lupus erythematosus-associated thrombocytopenia: results from a real-world CSTAR cohort study.Arthritis research & therapy · 2024Article
- Challenges in Treating Extensive Deep Vein Thrombosis with Severe Thrombocytopenia in Patients with Antiphospholipid Syndrome-A Follow-up of 2 Years.The International journal of angiology : official publication of the International College of Angiology, Inc · 2024Article
- Clinical Characteristics and Prognosis of Acute Pulmonary Embolism with Hemoptysis in Autoimmune Disease Patients.International journal of medical sciences · 2024Article
- Development of a risk prediction model for the first occurrence of thrombosis in patients with OAPS.Frontiers in immunology · 2024Article
- Serum Calprotectin as a Potential Predictor of Microvascular Manifestations in Patients with Antiphospholipid Syndrome.Rheumatology and therapy · 2023Article
- Prevalence and diagnostic value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome in Chinese patients.Frontiers in immunology · 2023Article
- Thrombocytopenia in a cohort of primary and secondary antiphospholipid syndrome patients: Relation to clinical, laboratory manifestations and damage index.Archives of rheumatology · 2022Article
- Pulmonary Endarterectomy in Patients with Antiphospholipid Syndrome-Associated Chronic Thromboembolic Pulmonary Hypertension.Anatolian journal of cardiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The association between antiphospholipid antibodies (aPL) and clinical problems goes beyond what is stated in the antiphospholipid syndrome (APS) classification criteria, namely thrombosis and pregnancy morbidity, and thrombocytopenia is the most common non-criteria hematologic manifestation of aPL with a frequency ranging from 20 to 50 %. Thrombocytopenia is rarely severe, and hemorrhage is far less common than thrombosis. However, when anticoagulation is considered, it may constitute a clinical problem with increased bleeding risk. Furthermore, thrombocytopenia represents a risk factor for thrombosis in aPL-positive patients. Therefore, it is important to understand the pathogenesis and the clinical associations of thrombocytopenia to build the right medical approach in aPL-positive patients. In this paper, we review the literature on aPL/APS-associated thrombocytopenia and briefly discuss the other conditions that can result in thrombocytopenia as they have commonalities with APS and their recognition is important to establish the most appropriate treatment strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.